All In Biotech

Free tool

FAERS Monitor: Tavalisse

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209299 or its brand name (Tavalisse, Fostamatinib Disodium). Reports on generic versions are filed under their own applications.

Reports

7,889

Serious

2,613

33% of reports

Hospitalization

1,819

Death reported

493

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea1,068
  • product dose omission issue1,026
  • platelet count decreased1,019
  • off label use873
  • hospitalisation508
  • platelet count498
  • drug ineffective433
  • fatigue403
  • blood pressure increased384
  • death342
  • product prescribing issue316
  • headache273
  • nausea250
  • dizziness229
  • hypertension208

Reports by year received

View as table
YearReports
20161
20171
2018155
2019619
2020650
2021454
2022773
20231,119
20241,302
20251,325
20261,490

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,270 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
platelet countSignal49816402.012982.81,140,301
product prescribing issueSignal31639.235.211,575
platelet count decreasedSignal1,01925.724.324,082
product dose omission issueSignal1,0269.38.87,705
hospitalisationSignal5088.88.13,539
blood pressure increasedSignal3846.76.11,869
diarrhoeaSignal1,0684.44.22,904
off label useSignal8732.72.5941
hypertensionSignal2082.62.3209
fatigue4031.41.343
dizziness2291.21.19
headache2731.21.06
death3421.11.01
drug ineffective4330.90.88
nausea2500.80.78

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.